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Introduction
Systemic juvenile idiopathic arthritis (SJIA) is an autoin-
flammatory rheumatic disease characterized by the
presence of intermittent spiking fever, evanescent erythe-
matous rash, arthritis, lymphadenopathy, hepatosplenome-
galy, serositis and elevated inflammatory markers. It
accounts for only 10-20% of all patients with JIA but is
associated with higher morbidity and mortality. Despite
the variety of treatments available, in some cases the dis-
ease is difficult to control and has a refractory course. The
recent knowledge of the key role of certain cytokines
(interleukin (IL)-1, IL-6 and IL-18) in its pathogenesis
makes them potential therapeutic targets. Anakinra is a
recombinant form of human IL-1 receptor antagonist (IL-
1Ra) that has been used in SJIA refractory cases and as
first line therapeutic agent in selected patients.
Objectives
To describe a case of clinical and imagiological complete
remission with Anakinra treatment in a patient with
SJIA and severe coxitis.
Methods
The authors report the case of a fourteen-year-old Cauca-
sian girl diagnosed with SJIA by the age of four, when she
presented with prolonged febrile syndrome, polyarthritis,
evanescent salmon pink rash and pericardial effusion. She
was initially treated with oral corticosteroids (prednisolone
1 mg/kg/day). In spite of clinical improvement, systemic
and articular activity of the disease persisted with 1-2
exacerbations a year and in the beginning of the year 2007
she started subcutaneous methotrexate (10 mg/week).
Despite methotrexate treatment escalation, the patient
developed severe left coxitis with major limitation of hip
joint mobility, which did not respond to triamcinolone
hexacetonide injection.
Results
Due to the persistence of arthritis and elevated inflamma-
tory markers she started Anakinra (1 mg/kg/day) in July
2009. Since then there has been sustained improvement
with resolution of clinical symptoms, normalization of
laboratory parameters and complete clinical and radiologi-
cal resolution of coxitis, which allowed discontinuation of
methotrexate and corticosteroids. Anakinra was well toler-
ated and there were no adverse events. The patient
achieved prolonged remission.
Conclusion
A significant number of patients with SJIA has persistent
disease despite the treatments used. In this case we
report the therapeutic success with Anakinra in a patient
with refractory systemic and articular manifestations
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